Fernandez et al. demonstrated that pharmaceutical blockade, either by antagonist or monoclonal antibody of the VEGF signaling molecules or receptors, effectively impeded neovascularization of portal-systemic collaterals and decreased portal blood inflow in rats with portal hypertension [17]. Here, VEGFA is linked to liver disorder.